Catalent Pharma Solutions
About Catalent Pharma Solutions
272 articles about Catalent Pharma Solutions
-
Cell and gene therapy professionals gathered in Miami last month to discuss new manufacturing approaches for these up-and-coming treatments.
-
After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.
-
Mergers and acquisitions are trending upward as Novo Nordisk, Gilead, and Johnson & Johnson kick off the year with big deals. AI and other scientific advances will likely be the focus of M&As yet to come.
-
Analysts say Novo Holdings made the right decision last week in scooping up the CDMO to increase manufacturing capacity for its diabetes and weight-loss drugs.
-
Novo’s Catalent Acquisition Surprises Some Analysts, Raises Questions about Existing Contracts
2/7/2024
While analysts are bullish on Novo Holdings’ $16.5 billion acquisition of Catalent, they say it raises questions for companies that have contracted the CDMO for manufacturing. -
The company’s fiscal report for 2023 details revenue losses of $539 million and layoffs of 1,100 employees but notes that future GLP-1 manufacturing revenues could help stabilize its finances.
-
Catalent, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will participate at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 at 5:15 p.m. EST.
-
Exelixis has inked a licensing agreement with Catalent to gain access to three of Catalent’s target programs with antibody and ADC candidates, the companies announced Thursday.
-
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
7/7/2022
Xenetic Biosciences, Inc. today announced it has entered into a manufacturing agreement with Catalent Pharma Solutions LLC ("Catalent"), which will include cGMP manufacturing for the Company's recombinant protein, Human DNase I.
-
A recent research report points to the CDMO market heating up. P&S projected the global biologics CDMO market would hit $31.839 million by 2030.
-
Several biopharma companies are closing out the month of April with expansions to facilities, including a $3 billion investment to develop next-generation life science ecosystems.
-
Several biopharma companies have adjusted their leadership teams to include new chief executive officers who are expected to guide the companies and their programs into the future.
-
A U.S. Congress subcommittee unanimously approved the ACT for ALS bill in a decision that could soon pour massive funding into the search for treatment for this debilitating and deadly disease.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
Earlier this month, Catalent announced plans to add 500–600 jobs in Bloomington, Ind., one of its Moderna and Johnson & Johnson COVID-19 vaccine manufacturing sites.
-
Moderna, one of three companies to have a COVID-19 vaccine authorized in the U.S., isn’t resting on its accomplishments but is instead working to scale up production further and improve on its vaccine.
-
CDMO Catalent continues its push to the top with yet another acquisition. Buying out Delphi Genetics, the manufacturing company can now add plasmid DNA production to its growing list of offerings.
-
Catalent, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference
2/19/2021
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the SVB Leerink 10th Annual Global Healthcare Conference at 11:20 a.m. ET on February 25, 2021.
-
SK Capital Announces Agreement to Acquire Catalent’s Blow-Fill-Seal Sterile CDMO Business
1/6/2021
SK Capital Partners LP, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, announced that funds it advises have signed a definitive agreement to acquire the Blow-Fill-Seal Sterile Contract Development and Manufacturing Business from Catalent Pharma Solutions, LLC.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.